McCall Patrick 4

What Happened Patrick McCall, Chief Financial Officer of IN8BIO, was granted a derivative award covering 75,000 shares on February 4, 2026. The Form 4 reports the acquisition price as $0.00 (typical for a grant); the filing classifies the transaction as a derivative award rather than an open-market purchase or sale. This is a compensation grant, not an immediate purchase or sale of shares.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026 (timely within the usual two-business-day window).
• Reported amount: 75,000 shares (derivative award); acquisition price reported as $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: 25% of the option shares vest on February 4, 2027; the remaining shares vest in 36 equal monthly installments thereafter, contingent on continued service.
• No indication of a 10b5-1 plan, cashless sale, tax-withholding disposition, or late filing in the provided details.

Context The report indicates an option-style grant (footnote refers to "shares subject to the option") that vests over several years. Because these are time‑vested compensation awards, they reflect executive compensation policy rather than an immediate directional bet on the stock; they only become exercisable/owned over the vesting schedule and may require exercise terms (price, expiration) not shown in the excerpt.